Overview

Investigating the Safety and Efficacy of SHR6508 Injection in the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients : A Multicenter, Long-term Clinical Trial

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, single-arm, long-term safety and tolerability trial. A total of 300 subjects with chronic kidney disease on hemodialysis are planned to be enrolled.
Phase:
PHASE2
Details
Lead Sponsor:
Shanghai Hengrui Pharmaceutical Co., Ltd.